Objective
lung cancer, pneumonitis, NSCLC, immune‐related adverse events
LUNG CANCER, PNEUMONITIS, NSCLC
Immunotherapy extensively treats advanced non‐small‐cell lung cancer (NSCLC). Although immunotherapy is generally better tolerated than chemotherapy, it can cause multiple immune‐related adverse events (irAEs) involving multiple organs. Checkpoint inhibitor‐related pneumonitis (CIP) is a relatively uncommon irAE that, in severe cases, can be fatal. Potential risk factors for the occurrence of CIP are currently poorly understood. This study sought to develop a novel scoring system for predicting the risk of CIP based on a nomogram model.